ReviewSensors (Basel, Switzerland)2026
Machine Learning for Radiomics in Oncology: Challenges, Limitations, and Future Directions.
Review in Sensors (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
In precision oncology, the combination of the strengths of both histopathology and medical imaging provides a fertile ground for tumor characterization. Although histopathology offers a definitive cellular diagnosis, this approach is invasive and only provides a small-scale characterization of the tumor, while medical imaging modalities, such as X-ray, CT, MRI, ultrasound, and PET scans, provide a complete characterization of the tumor but, until recently, relied on the subjective ability of a human observer. The application of machine learning to radiomics aims at filling this gap, as images are mined to reveal patterns of disease not visible to the naked eye. In this perspective paper, the trajectory of machine learning in radiomics for oncology applications is critically discussed. By exploring studies using different imaging modalities, we seek to look beyond the achievements of innovative algorithms and identify the systemic weaknesses in the field, which are holding it back from translating to the clinic. In this regard, we identify two major challenges in the field: the significant effects of inter-modality and inter-scanner variability in model generalizability, and the 'interpretability gaps' in understanding the rationale for the decision-making process in ML algorithms. In this paper, we assert that these challenges are holding back even the best of algorithms and thus set the direction for the field in the future, advocating for the development of ML systems with emphasis on their performance in real-world settings as opposed to the lab.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.